Johnson & Johnson announced that they will make a commitment of up to $200 million to move forward to create an Ebola vaccine program at its Janssen Pharmaceutical Companies. The company is working with other organizations such as the World Health Organization (WHO) and the National Institute of Allergy and Infectious Diseases (NIAID).
In addition, Johnson & Johnson says it will work with other key stakeholders, governments, and public health authorities on the clinical testing, development, production and distribution of the vaccine regimen.
“We are urgently working to provide our vaccine expertise, production capabilities, our people and resources to address the Ebola crisis,” said Alex Gorsky, Chairman and CEO, Johnson & Johnson, in a statement. “Our innovation model enables us to quickly mobilize our extensive resources to collaborate with health authorities and governments and other experts to help contain this disease, save lives, and protect the health and lives of those at risk. We have an important responsibility as a leading global healthcare company to do all we can to address this urgent unmet medical need.”
For more information on our Ebola coverage, see Watch Out for Ebola Charity Scams.